short term tirzepatide as Adjunct to Insulin in Adults With Type 1 Diabetes and Overweight or Obesity: A Systematic Review of Randomized and Real‐World Evidence GLP-1 Drug, Tirzepatide May Offer
Description
The approval was based on data from two randomized, double-blind, placebo-controlled studies involving more than 3,000 overweight or obese adults
95% CI, 0.78-0.85) reduced risk for cardiovascular events compared with sulfonylureas users
Once reconstituted, store at 4C and use within 28 days
The most important factor isnt the exact medication, but how its prescribed, monitored, and supported
After 20 years of exclusivity, other companies can now develop generic or similar versions, subject to regulatory approval
